Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research applications. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
Our tirzepatide near me is available in pharmaceutical grade purity (99+%) with customizable packaging options. The product shows preferential binding to GIP receptors while maintaining significant GLP-1 receptor activity, making it particularly effective for metabolic research applications.
As a manufacturer, we offer flexible packaging solutions including 10mg/vial, 15mg/vial, 20mg/vial, and 30mg/vial configurations. Custom concentrations and labeling options are available for bulk research orders.
For research use only. Not for human consumption.